NYSEAMERICAN:KAPA Kairos Pharma Q2 2026 Earnings Report $1.72 -0.05 (-2.82%) Closing price 04:10 PM EasternExtended Trading$1.72 +0.00 (+0.12%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Kairos Pharma EPS ResultsActual EPS-$0.42Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AKairos Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AKairos Pharma Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Kairos Pharma Earnings HeadlinesKairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MASeptember 23 at 9:00 AM | marketscreener.comMKairos Pharma consensus price target increased by 600.00% to $49.98September 15, 2026 | msn.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 25 at 1:00 AM | InvestorPlace (Ad)Kairos Pharma (NYSEAMERICAN:KAPA) Stock Price Up 4.7% - Should You Buy?September 15, 2026 | americanbankingnews.comKairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 9, 2026 | finance.yahoo.comKairos Pharma Announces 1-for-7 Reverse Stock SplitAugust 21, 2026 | businesswire.comSee More Kairos Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kairos Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kairos Pharma and other key companies, straight to your email. Email Address About Kairos PharmaKairos Pharma (NYSEAMERICAN:KAPA) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on immuno-oncology, with an emphasis on addressing mechanisms that can cause tumors to resist existing treatments. Kairos Pharma’s lead program, KPA-1102, is an investigational antibody designed to inhibit leukemia inhibitory factor (LIF), a signaling protein associated with tumor growth and immune suppression. The company is evaluating the potential use of this approach in combination with other cancer therapies, including immune checkpoint inhibitors. The company is based in the United States and is focused primarily on advancing its drug candidates through clinical development and regulatory processes. As an emerging biotechnology company, Kairos Pharma’s operations and product portfolio remain centered on research, clinical trials and the development of its oncology pipeline.View Kairos Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
